EckelRH, JakicicJM, ArdJD, et al.American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129:S76–S99.
2.
European Association for Cardiovascular Prevention and Rehabilitation; ReinerZ, CatapanoAL, De BackerG, et al.ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32:1769–1818.
3.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129:S1–S45.
4.
CooneyMT, DudinaA, d'AgostinoR, GrahamIM. Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future?. Circulation, 2010; 122:300–310.
5.
GoffDC, Lloyd-JonesDM, BennettG, et al.2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63:2935–2959.
6.
FalkE, ShahPK. The SHAPE guideline: Ahead of its time or just in time?. Curr Atheroscler Rep, 2011; 13:345–352.
7.
BrindlePM, McConnachieA, UptonMN, HartCL, Davey SmithG, WattGCM. The accuracy of the Framingham risk-score in different socioeconomic groups: A prospective study. Br J Gen Pract, 2005; 55:838–845.
8.
BrindleP, JonathanE, LampeF, et al.Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. BMJ, 2003; 327:1267.
9.
MichosaED, NasiraK, BraunsteinaJB, et al.Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis, 2006; 184:201–206.
10.
LauerMS. Primary prevention of atherosclerotic cardiovascular disease: The high public burden of low individual risk. JAMA, 2007; 297:1376–1378.
11.
BrotmanDJ, WalkerE, LauerMS, O'BrienRG. In search of fewer independent risk factors. Arch Intern Med, 2005; 165:138–145.
12.
WareJH. The limitations of risk factors as prognostic tools. N Engl J Med, 2006; 355; 2615–2617.
13.
PencinaMJ, D'AgostinoRB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med, 2004; 23:2109–2123.
14.
NaghaviM, FalkE, HechtHS, et al.From vulnerable plaque to vulnerable patient–Part III: Executive summary of the Screening for Heart Attack Prevention and Education Task Force report. Am J Cardiol, 2006; 98:2H–15H.
15.
ShahPK. Screening asymptomatic subjects for subclinical atherosclerosis: Can we, does it matter, and should we?. J Am Coll Cardiol, 2010; 56:98–105.
16.
GreenlandP, AlpertJS, BellerGA, et al.2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2010; 56:e50–e103.
17.
KarmD, MarksDS, WeinM, KongAL. Benign arterial calcification on screening mammogram: A marker for coronary artery disease?. J Womens Health, 2015; 24:795–800.
18.
MaasAH, van der SchouwYT, AtsmaF, et al.Breast arterial calcifications are correlated with subsequent development of coronary artery calcifications, but their aetiology is predominantly different. Radiology, 2007; 63:396–400.
19.
RafehNA, CastellanosMR, KhoueiryGT, et al.Association between coronary artery disease diagnosed by coronary angiography and breast arterial calcifications on mammography: Meta-analysis of the data. J Womens Health, 2012; 21:1053–1058.
20.
PletcherMJ, PignoneM. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation, 2011; 123; 1116–1124.
